MTOR and neoplasm: The anti-proliferative properties of mTOR inhibitors in preclinical models would be of high value in patients with HCC as they would allow to prevent tumor recurrence after potentially curative therapies (i.e., percutaneous tumor ablation, surgical resection or liver transplantation), or to delay tumor progression in patients with a more advanced disease.